Research desk / two listings
NMN vs NR: NAD+ Precursors in Human Trials
Two precursor listings read side by side — the doses, the measured blood-NAD+ rises, and the biochemistry that separates them — with the coenzyme-versus-precursor line kept exact.
The short read
This page puts NMN vs NR side by side. Both are precursors (building blocks the body turns into NAD+), and both reliably raise blood NAD+ in human trials — they just take slightly different biochemical routes to get there [3][4]. NR (nicotinamide riboside) is the most studied; NMN (nicotinamide mononucleotide) is one chemical step closer to NAD+. Neither is NAD+ itself, which is why a bottle labeled "NAD+" almost always contains one of these instead. Below, each is its own listing with its own measured quote.
NMN (nicotinamide mononucleotide)
NMN is a direct NAD+ precursor sitting one biochemical step from NAD+ — the salvage pathway converts NMN to NAD+ via the enzyme NMNAT [5]. In human trials, oral NMN at 300, 600, or 900 mg/day for 60 days raised blood NAD+ at days 30 and 60 across every dose group versus placebo (p ≤ 0.001) in a multicenter, double-blind, randomized trial, which identified 600 mg/day as optimal and reported improved walking distance with no safety issues [3]. A separate 10-week trial at 250 mg/day improved muscle insulin sensitivity in prediabetic, postmenopausal women without changing body composition [1]. NMN is the listing whose regulatory status is contested — the FDA has taken the position it is excluded from the dietary-supplement definition because it was investigated as a drug, a marketplace dispute rather than a ban [21].
NR (nicotinamide riboside)
NR is a vitamin-B3-family NAD+ precursor and the most clinically studied oral NAD+ booster. It is converted to NMN by the NRK1/NRK2 kinases — a NAMPT-independent route whose structural basis was defined from crystal structures of human NRK1 — and then to NAD+ [12]. In healthy overweight adults, NR at 100, 300, and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with no flushing, no LDL elevation, and no significant adverse-event difference from placebo at any dose [4]. NR also anchors the strongest rare-disease data: a 52-week Werner-syndrome RCT (n=9) produced a roughly 140% plasma NAD+ rise with improved arterial stiffness and kidney function [13], and it is the precursor used in the long-COVID and Parkinson's trials [14][8].
NMN vs NR: how each raises blood NAD+
Read as two order-book listings, the precursors converge on the same outcome by different paths. NR enters through the NRK kinases to become NMN, then NAD+; NMN is already at the NMN node and converts onward via NMNAT [5]. Both produce dose-dependent, sustained whole-blood NAD+ elevation across multi-week dosing [3][4]. The cleanest dose-response quote belongs to NR (+22%/51%/142% at 100/300/1000 mg/day) [4]; NMN's multicenter trial confirms the same direction at 300-900 mg/day and adds a functional walking-distance signal [3]. Head-to-head efficacy on hard clinical endpoints has not been established for either — a 2025 review concluded human efficacy data overall remain preliminary [21].
Tolerability, side by side
On safety, the two listings read similarly clean in the controlled record. NR showed no flushing and no significant adverse-event difference from placebo across 100-1000 mg/day for 8 weeks, and did not elevate LDL cholesterol or disrupt one-carbon metabolism [4]. NMN reported no safety issues across 300-900 mg/day over 60 days in the multicenter trial [3], and across the rare-disease NR trials no moderate or severe adverse events were recorded [13]. The unsettled questions are not acute tolerability but the open human-efficacy ceiling that applies to both [21] and, for NMN specifically, the contested supplement status [21]. Both forms are also hygroscopic and degrade with heat and moisture, so product quality and actual content vary between manufacturers.
Why 'NAD+' on a label usually means a precursor
Intact oral NAD+ is poorly taken up by cells, so a product that simply packed NAD+ into a capsule would deliver little usable dose [21]. That is why the rational oral approaches — and nearly all the controlled human evidence — use precursors that the body converts into NAD+ [3][4]. A bottle labeled "NAD+" therefore almost always contains NMN, NR, or plain niacin/nicotinamide. Keeping that distinction exact is the whole point of reading these as separate listings: an oral-NMN or oral-NR trial is never "taking NAD+," and neither is the same as the IV route covered on NAD+ and the brain.
Why 'NAD+' on a label usually means a precursor (the short version)
Because the intact coenzyme barely absorbs by mouth, oral "NAD+" products are almost always the precursors NMN or NR, which the body converts into NAD+ [21]. The precursor — not NAD+ itself — is what the trials measured raising blood NAD+ [3][4].
Is taking NAD orally effective?
Intact oral NAD+ is poorly absorbed, so studies use precursors instead. Oral NMN and NR reliably and dose-dependently raise blood NAD+ — NR raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day [4], and NMN raised it across 300-900 mg/day in a randomized trial [3]. Whether that yields a clinical benefit is unproven [21].